المؤلفون: Douglas, Cameron, Hewitt, Lyndel, Yabe, Takako Eva, Mitchell, Jenny, Ashford, Bruce

المصدر: World Journal of Oncology ; volume 14, issue 2, page 150-157 ; ISSN 1920-4531 1920-454X

الإتاحة: https://doi.org/10.14740/wjon1541Test
http://www.wjon.org/index.php/WJON/article/download/1541/1309Test

المؤلفون: Quickfall, Aimee, Mitchell, Jenny, Cooper, Jodie

المصدر: Quickfall , A , Mitchell , J & Cooper , J 2024 , ' Online focus groups with student teachers who are also parents : co-creation with student researchers ' , SAGE Research Methods .

العلاقة: https://research.leedstrinity.ac.uk/en/publications/5f5c53db-2fef-41fd-8963-d74df8d85141Test

الإتاحة: https://research.leedstrinity.ac.uk/en/publications/5f5c53db-2fef-41fd-8963-d74df8d85141Test

المؤلفون: Minaei, Elahe, Mueller, Simon A, Ashford, Bruce, Thind, Amarinder Singh, Mitchell, Jenny, Perry, Jay R, Genenger, Benjamin, Clark, Jonathan R, Gupta, Ruta, Ranson, Marie

المصدر: Minaei, Elahe; Mueller, Simon A; Ashford, Bruce; Thind, Amarinder Singh; Mitchell, Jenny; Perry, Jay R; Genenger, Benjamin; Clark, Jonathan R; Gupta, Ruta; Ranson, Marie (2022). Cancer Progression Gene Expression Profiling Identifies the Urokinase Plasminogen Activator Receptor as a Biomarker of Metastasis in Cutaneous Squamous Cell Carcinoma. Frontiers in oncology, 12, p. 835929. Frontiers Research Foundation 10.3389/fonc.2022.835929

مصطلحات موضوعية: 610 Medicine & health

الوصف: Cutaneous squamous cell carcinoma (cSCC) of the head and neck region is the second most prevalent skin cancer, with metastases to regional lymph nodes occurring in 2%-5% of cases. To further our understanding of the molecular events characterizing cSCC invasion and metastasis, we conducted targeted cancer progression gene expression and pathway analysis in non-metastasizing (PRI-) and metastasizing primary (PRI+) cSCC tumors of the head and neck region, cognate lymph node metastases (MET), and matched sun-exposed skin (SES). The highest differentially expressed genes in metastatic (MET and PRI+) versus non-metastatic tumors (PRI-) and SES included PLAU, PLAUR, MMP1, MMP10, MMP13, ITGA5, VEGFA, and various inflammatory cytokine genes. Pathway enrichment analyses implicated these genes in cellular pathways and functions promoting matrix remodeling, cell survival and migration, and epithelial to mesenchymal transition, which were all significantly activated in metastatic compared to non-metastatic tumors (PRI-) and SES. We validated the overexpression of urokinase plasminogen activator receptor (uPAR, encoded by PLAUR) in an extended patient cohort by demonstrating higher uPAR staining intensity in metastasizing tumors. As pathway analyses identified epidermal growth factor (EGF) as a potential upstream regulator of PLAUR, the effect of EGF on uPAR expression levels and cell motility was functionally validated in human metastatic cSCC cells. In conclusion, we propose that uPAR is an important driver of metastasis in cSCC and represents a potential therapeutic target in this disease.

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/176630Test/

الإتاحة: https://doi.org/10.3389/fonc.2022.835929Test
https://boris.unibe.ch/176630/1/fonc-12-835929.pdfTest
https://boris.unibe.ch/176630Test/

المؤلفون: Thind, Amarinder Singh, Ashford, Bruce, Strbenac, Dario, Mitchell, Jenny, Lee, Jenny, Mueller, Simon A, Minaei, Elahe, Perry, Jay R, Ch'ng, Sydney, Iyer, N Gopalakrishna, Clark, Jonathan R, Gupta, Ruta, Ranson, Marie

المصدر: Thind, Amarinder Singh; Ashford, Bruce; Strbenac, Dario; Mitchell, Jenny; Lee, Jenny; Mueller, Simon A; Minaei, Elahe; Perry, Jay R; Ch'ng, Sydney; Iyer, N Gopalakrishna; Clark, Jonathan R; Gupta, Ruta; Ranson, Marie (2022). Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma. Frontiers in oncology, 12, p. 919118. Frontiers Research Foundation 10.3389/fonc.2022.919118

مصطلحات موضوعية: 610 Medicine & health

الوصف: Metastatic cutaneous squamous cell carcinoma (CSCC) is a highly morbid disease requiring radical surgery and adjuvant therapy, which is associated with a poor prognosis. Yet, compared to other advanced malignancies, relatively little is known of the genomic landscape of metastatic CSCC. We have previously reported the mutational signatures and mutational patterns of CCCTC-binding factor (CTCF) regions in metastatic CSCC. However, many other genomic components (indel signatures, non-coding drivers, and structural variants) of metastatic CSCC have not been reported. To this end, we performed whole genome sequencing on lymph node metastases and blood DNA from 25 CSCC patients with regional metastases of the head and neck. We designed a multifaceted computational analysis at the whole genome level to provide a more comprehensive perspective of the genomic landscape of metastatic CSCC. In the non-coding genome, 3' untranslated region (3'UTR) regions of EVC (48% of specimens), PPP1R1A (48% of specimens), and ABCA4 (20% of specimens) along with the tumor-suppressing long non-coding RNA (lncRNA) LINC01003 (64% of specimens) were significantly functionally altered (Q-value < 0.05) and represent potential non-coding biomarkers of CSCC. Recurrent copy number loss in the tumor suppressor gene PTPRD was observed. Gene amplification was much less frequent, and few genes were recurrently amplified. Single nucleotide variants driver analyses from three tools confirmed TP53 and CDKN2A as recurrently mutated genes but also identified C9 as a potential novel driver in this disease. Furthermore, indel signature analysis highlighted the dominance of ID signature 13 (ID13) followed by ID8 and ID9. ID9 has previously been shown to have no association with skin melanoma, unlike ID13 and ID8, suggesting a novel pattern of indel variation in metastatic CSCC. The enrichment analysis of various genetically altered candidates shows enrichment of "TGF-beta regulation of extracellular matrix" and "cell cycle G1 to S check points." These ...

وصف الملف: application/pdf

العلاقة: https://boris.unibe.ch/176631Test/

الإتاحة: https://doi.org/10.3389/fonc.2022.919118Test
https://boris.unibe.ch/176631/1/fonc-12-919118.pdfTest
https://boris.unibe.ch/176631Test/

المؤلفون: Kho, Jason, Mitchell, Jenny, Curry, Nicola, Di Chiara, Francesco, Stavroulias, Dionisios, Belcher, Elizabeth

المصدر: The Journal of Thoracic and Cardiovascular Surgery ; volume 164, issue 6, page 1603-1611.e1 ; ISSN 0022-5223

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, Surgery

الإتاحة: https://doi.org/10.1016/j.jtcvs.2022.06.016Test
https://api.elsevier.com/content/article/PII:S0022522322007127?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0022522322007127?httpAccept=text/plainTest

المؤلفون: Mitchell, Jenny

المصدر: Studies in the Maternal ; ISSN 1759-0434

الإتاحة: https://doi.org/10.16995/sim.4358Test
http://mamsie.olh.janewaysharedhosting.com/article/id/4358Test/

المؤلفون: Belcher, Elizabeth, Mitchell, Jenny, Stavroulias, Dionisios, Di Chiara, Francesco, Rahman, Najib

المصدر: BMJ Open Respiratory Research ; volume 8, issue 1, page e000771 ; ISSN 2052-4439

مصطلحات موضوعية: Pulmonary and Respiratory Medicine

الوصف: Background The optimal resection rate for institutions managing early-stage primary lung cancer is not known. Whether the prognosis of patients who do not proceed to operation is determined by their comorbidities for which they were deemed at prohibitively high-operative risk, or disease progression, is uncertain. We investigated the outcomes of patients with early-stage lung cancer who were considered for surgical management. Methods We reviewed the outcomes of consecutive patients who were considered for resection of early-stage primary lung cancer at Oxford University Hospitals National Health Service Foundation Trust between 2012 and 2017. Results Between 29 November 2012 and 31 March 2017, 467 consecutive patients underwent resection with curative intent for primary lung cancer (operative group), while 81 patients were deemed resectable but either inoperable or did not wish to proceed to operation (non-operative group). Reason for not proceeding to resection was cardiovascular in 16 patients (19.8%), respiratory in 21 (25.9%), cardiorespiratory in 11 (13.6%), performance status in 8 (9.9%) and patient choice in 25 (30.9%) patients. Sixty-six patients (81.5%) received an alternative radical treatment. Median follow-up was 169 weeks (IQR 119–246 weeks) in the operative group and 118 weeks (IQR 74–167 weeks) in the non-operative group. Median survival of patients with early-stage lung cancer who did not proceed to operation was 2.5 years; median survival of patients undergoing lung cancer resection was undefined (p<0.0001). Lung cancer was documented as directly or indirectly leading to or contributing to death in 40 patients (76.9%). In 11 patients, the cause of death was due to comorbidities (21.2%). Conclusions Patients turned down for operation in a high-resection rate UK unit have limited survival due to lung cancer progression. We conclude that ‘optimal’ resection rates may not have been reached in the UK even in high-resection rate centres.

الإتاحة: https://doi.org/10.1136/bmjresp-2020-000771Test

المؤلفون: Mitchell, Jenny

المصدر: Volume: 13 ; Issue: 1 ; JournalTitle: Studies in the Maternal ; 1759-0434

الوصف: A collection of poems.

العلاقة: https://doi.org/10.16995/sim.291Test; /article/id/4300/

الإتاحة: https://doi.org/10.16995/sim.291Test

المؤلفون: Gupta, Ruta, Strbenac, Dario, Satgunaseelan, Laveniya, Cheung, Veronica Ka Yan, Narayanappa, Harini, Ashford, Bruce, Mitchell, Jenny, Thind, Amarinder, Palme, Carsten E., Ch'ng, Sydney, Low, Tsu Hui Hubert, Wykes, James, Willet, Cali E., Chew, Tracy, Yang, Jean, Ranson, Marie, Clark, Jonathan R.

المصدر: Scopus Harvesting Series

مصطلحات موضوعية: cutaneous, head and neck, keratinizing squamous cell carcinoma, mutation signature, tumor mutation burden, whole-genome sequencing

الوصف: Squamous cell carcinoma is the most common head and neck malignancy arising from the oral mucosa and the skin. The histologic and immunohistochemical features of oral squamous cell carcinoma (OSCC) and head and neck cutaneous squamous cell carcinoma (HNcSCC) are similar, making it difficult to identify the primary site in cases of metastases. With the advent of immunotherapy, reliable distinction of OSCC and HNcSCC at metastatic sites has important treatment and prognostic implications. Here, we investigate and compare the genomic landscape of OSCC and HNcSCC to identify diagnostically useful biomarkers. Whole-genome sequencing data from 57 OSCC and 41 HNcSCC patients were obtained for tumor and matched normal samples. Tumor mutation burden (TMB), Catalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures, frequent chromosomal alterations, somatic single nucleotide, and copy number variations were analyzed. The median TMB of 3.75 in primary OSCC was significantly lower (P < .001) than that of 147.51 mutations/Mb in primary HNcSCC. The COSMIC mutation signatures were significantly different (P < .001) between OSCC and HNcSCC. OSCC showed COSMIC single-base substitution (SBS) mutation signature 1 and AID/APOBEC activity-associated signature 2 and/or 13. All except 1 HNcSCC from hair-bearing scalp showed UV damage-associated COSMIC SBS mutation signature 7. Both OSCC and HNcSCC demonstrated a predominance of tumor suppressor gene mutations, predominantly TP53. The most frequently mutated oncogenes were PIK3CA and MUC4 in OSCC and HNcSCC, respectively. The metastases of OSCC and HNcSCC demonstrated TMB and COSMIC SBS mutation signatures similar to their primary counterparts. The combination of high TMB and UV signature in a metastatic keratinizing squamous cell carcinoma suggests HNcSCC as the primary site and may also facilitate decisions regarding immunotherapy. HNcSCC and OSCC show distinct genomic profiles despite histologic and immunohistochemical similarities. Their genomic characteristics ...

العلاقة: https://ro.uow.edu.au/test2021/9221Test; https://doi.org/10.1016/j.modpat.2023.100190Test

الإتاحة: https://doi.org/10.1016/j.modpat.2023.100190Test
https://ro.uow.edu.au/test2021/9221Test

المؤلفون: Mitchell, Jenny, Benamore, Rachel, Gleeson, Fergus, Belcher, Elizabeth

المصدر: European Journal of Cardio-Thoracic Surgery ; ISSN 1010-7940 1873-734X

مصطلحات موضوعية: Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine, General Medicine, Surgery

الوصف: OBJECTIVES The optimal imaging programme for the follow-up of patients who have undergone resection of primary lung cancer is yet to be determined. We investigated the incidence and patterns of new and recurrent malignancy after resection for early-stage lung cancer in patients enrolled into a computed tomography (CT) follow-up programme. METHODS We reviewed the outcomes of consecutive patients who underwent CT follow-up after resection of early-stage primary lung cancer at the Oxford University Hospitals NHS Foundation Trust, between 2013 and 2017. RESULTS Four hundred and sixty-six consecutive patients underwent resection of primary lung cancer between 1 January 2013 and 31 March 2017. Three hundred and thirty-one patients (71.0%) were enrolled in CT follow-up. The median follow-up was 98 weeks (range 26–262). Sixty patients (18.2%) were diagnosed with programme-detected malignancy. Recurrence was diagnosed in 36 patients (10.9%), new primary lung cancer in 16 patients (4.8%) and non-lung primary tumours in 8 patients (2.4%). A routine CT scan identified the majority of new primary lung cancers (84.2%) and those with disease recurrence (85.7%). The majority of programme-detected malignancies were radically treatable (55%). The median survival of programme-detected cancers was 92.4 versus 23.0 weeks for patients with clinically detected tumours (P < 0.0001). Utilizing the CT scout image as a surrogate for chest X-ray, the sensitivity of this modality was 16.95% (8.44–28.97%) and specificity was 89.83% (79.17–96.18%). Negative likelihood ratio was 0.92 (0.8–1.07). CONCLUSIONS CT follow-up of surgically treated primary lung cancer patients identifies malignancy at a stage where radical treatment is possible in the majority of patients. Chest X-ray follow-up may not be of benefit following lung cancer resection.

الإتاحة: https://doi.org/10.1093/ejcts/ezz284Test